Posaconazole: an extended-spectrum triazole antifungal agent
about
VNI cures acute and chronic experimental Chagas diseaseStructural Insights into Inhibition of Sterol 14 -Demethylase in the Human Pathogen Trypanosoma cruziNLLSS: Predicting Synergistic Drug Combinations Based on Semi-supervised LearningEffect of the piperazine unit and metal-binding site position on the solubility and anti-proliferative activity of ruthenium(II)- and osmium(II)- arene complexes of isomeric indolo[3,2-c]quinoline-piperazine hybrids.Sixty-year-old man with slowly expanding nodular plaque on the thighDrug strategies targeting CYP51 in neglected tropical diseasesStrong effect of copper(II) coordination on antiproliferative activity of thiosemicarbazone-piperazine and thiosemicarbazone-morpholine hybrids.Targeting Trypanosoma cruzi sterol 14α-demethylase (CYP51)Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazoleInvasive mould infections of the naso-orbital region of cats: a case involving Aspergillus fumigatus and an aetiological review.Antifungal prophylaxis during treatment for haematological malignancies: are we there yet?Safety of posaconazole.Cryptococcosis as an emerging systemic mycosis in dogs.Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.Role of posaconazole in the treatment of oropharyngeal candidiasisAntimicrobial and antiurease activities of newly synthesized morpholine derivatives containing an azole nucleus.Hot melt extruded amorphous solid dispersion of posaconazole with improved bioavailability: investigating drug-polymer miscibility with advanced characterisation.Successful use of posaconazole to treat invasive cutaneous fungal infection in a liver transplant patient on sirolimus.Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview.Drug disposition before and after gastric bypass: fenofibrate and posaconazole.[Candida glabrata : pathogenicity and therapy update].A routine method for the quantification of the novel antimycotic drug posaconazole in plasma using liquid chromatography-tandem mass spectrometry.Hyperbaric Oxygen Reduces Aspergillus fumigatus Proliferation In Vitro and Influences In Vivo Disease Outcomes.Piperazinyl fragment improves anticancer activity of Triapine.Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients.Imidazole and Triazole Coordination Chemistry for Antifouling Coatings
P2860
Q24604994-4685A0AB-7D02-4047-BE9D-FAE605E6CCDFQ27662136-96692FD9-AC95-4793-9DAB-DCF77E028A7FQ28552626-A67FA2F7-A0D3-4006-AA0D-6C53717C570FQ33864513-8648468E-90FC-41B4-BADA-23BC2B036159Q34362577-3499C5D6-D2CD-4EA2-BB73-89CF5949F576Q34622554-F7B40657-FBE5-4237-ABA9-301F10A666C4Q35610388-D7CEE119-9D4E-4654-9293-3288C8E940DEQ36368984-78DD7464-BEF1-423A-BFE4-AB776D12D75DQ36521993-07DC01BC-3678-45B9-B4A7-16F6FF4A2927Q37783654-7A273A89-CDD4-4442-BED0-A8658285AA0EQ37866827-534C139E-6A63-4F0A-8FD1-0F6EF3F924E7Q38077591-4E6DAE7D-0EF6-44F5-9E34-9EE1E242D28DQ38131855-61C73AFA-D1D9-44FE-BA2C-381715BFC38DQ38193337-5179745A-2E68-449E-872B-C456EB82EEEBQ41788151-B0CC264F-F177-41BC-8237-AF6BE0535AF6Q41842051-6A80BEB4-9644-48B7-B7D7-75ADFACB59B4Q41980730-672C2BE7-3963-4ACE-AC10-9D1574D4AAA8Q42114941-EFAE1643-1147-45B6-B9F5-91390118461CQ42184957-8416593B-6F09-4668-980A-3549E8E3B7D1Q42413286-B9E8F347-9EF1-4C7D-966D-7A9EB9D96DB0Q42700900-B822E928-4DCF-4B58-ACAE-B9FA608584B0Q44147815-D3374827-6F51-45DD-A1C2-9220507EA02EQ45172325-26A75426-B7F9-423A-914D-3DE622E12F75Q49921671-7D8B6AF2-B4E1-4727-ABDD-9B96D764FBA2Q52589888-0B42E17B-ACFB-4571-9F92-BCA03C5ECFBDQ55236793-A43111D0-C4E1-45D1-8821-7EC6D679C07AQ59011616-E8855C01-8E6D-4223-81FF-49D2B4E6569C
P2860
Posaconazole: an extended-spectrum triazole antifungal agent
description
2007 nî lūn-bûn
@nan
2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Posaconazole: an extended-spectrum triazole antifungal agent
@ast
Posaconazole: an extended-spectrum triazole antifungal agent
@en
Posaconazole: an extended-spectrum triazole antifungal agent
@nl
type
label
Posaconazole: an extended-spectrum triazole antifungal agent
@ast
Posaconazole: an extended-spectrum triazole antifungal agent
@en
Posaconazole: an extended-spectrum triazole antifungal agent
@nl
prefLabel
Posaconazole: an extended-spectrum triazole antifungal agent
@ast
Posaconazole: an extended-spectrum triazole antifungal agent
@en
Posaconazole: an extended-spectrum triazole antifungal agent
@nl
P3181
P1476
Posaconazole: an extended-spectrum triazole antifungal agent
@en
P2093
Daryl S Schiller
Horatio B Fung
P304
P3181
P356
10.1016/J.CLINTHERA.2007.09.015
P407
P577
2007-09-01T00:00:00Z